Puma Biotechnology, Inc. (PBYI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Puma Biotechnology, Inc. (PBYI) closed at USD 10.20 on 2026-10-14, a change of +94.3 % over the past year, with a market capitalization of USD 543.04M.

Puma Biotechnology, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Puma Biotechnology, Inc. key figures

Previous close

USD 10.20 (2026-10-14)

1-year change

+94.3 %

Market cap

USD 543.04M

Enterprise value

USD 453.96M

P/E ratio (trailing)

19.85

P/E ratio (forward)

30.06

EPS (trailing)

0.53

EPS (forward)

0.35

PEG ratio

n/a

Price to book

3.88

Revenue growth

7.8 %

Earnings growth

35.8 %

Dividend per share (trailing)

0.00

Short ratio

13.84

Employees

179

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Puma Biotechnology, Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Puma Biotechnology, Inc. and compare it with other stocks.